Skip to search formSkip to main contentSkip to account menu

CLC604

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
CLC604 preferentially inhibits the growth of HER2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of Taxol in vitro and in vivo.
HER2 has become a solicitous therapeutic target in metastatic and clinical drug-resistant cancer. Here, we evaluated whether or… 
2013
2013
CLC 604 preferentially inhibits the growth of HER 2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of Taxol in vitro and in vivo
HER2 has become a solicitous therapeutic target in metastatic and clinical drug-resistant cancer. Here, we evaluated whether or… 
2009
2009
What is the Key Point for Designing HER2 Inhibitors?
HER2 over-expression associates with many cancer symptoms, and the HER2 protein kinase was regarded as the target for cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)